We're currently experiencing phone and Internet issues in our call center, which may result in dropped calls or extended wait times. We're sorry for the inconvenience and are working to get it resolved as quickly as possible.
Sorry, we currently do not carry this product.
roe la' pi tant[Posted 01/16/2018] AUDIENCE: Pharmacy, Oncology, Nursing ISSUE: Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported in the postmarketing setting, some requiring hospitalization. These reactions have occurred during or soon after the infusion of rolapitant injectable emulsion. Most reactions have occurred within the first few minutes of administration. Symptoms of anaphylaxis can include wheezing or difficulty breathing; swelling of the face or throat; hives or flushing; itching; abdominal cramping, abdominal pain or vomiting; back pain or chest pain; hypotension or shock. See the Health Care Provider Letter, available at: http://bit.ly/2mDISBr, for important prescribing information to reflect the new safety information. BACKGROUND: Rolapitant injectable emulsion is approved to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Rolapitant is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy. RECOMMENDATION: Healthcare professionals must be vigilant for signs of hypersensitivity or anaphylaxis in all patients receiving rolapitant injectable emulsion, both during and following its administration. It is advised that Healthcare professionals consult with patients to determine if the patient is hypersensitive to any component of the product (including soybean oil). Furthermore, as cross reactions to other allergens is possible, patients with known allergies to legumes or other related allergens should be monitored closely. Patients with a potential hypersensitivity should not be administered rolapitant injectable emulsion. Appropriate treatment should be available for immediate use in the event of an anaphylactic reaction during treatment with rolapitant injectable emulsion. If anaphylaxis or any other serious hypersensitivity/infusion reaction occurs,